Morning Watch List: Starbucks Corporation (NASDAQ:SBUX), MarkWest Energy Partners, L.P. (NYSE:MWE), Ford Motor Company (NYSE:F), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), Gilead Sciences (NASDAQ:GILD)

Starbucks Corporation (NASDAQ:SBUX) belongs to Services sector. Its net profit margin is 14.60% and weekly performance is 2.56%. On last trading day company shares ended up $55.70. Starbucks Corporation (NASDAQ:SBUX) distance from 50-day simple moving average (SMA50) is 6.95%. Starbucks Corporation (NASDAQ:SBUX) is teaming up with more than a dozen companies in a commitment to increase hiring of young, minority workers over the next three years.

MarkWest Energy Partners, L.P. (NYSE:MWE) shares increased 13.96% in last trading session and ended the day at $68.09. MWE Gross Margin is 48.60% and its return on assets is 1.00%. MarkWest Energy Partners, L.P. (NYSE:MWE) quarterly performance is 6.45%. Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MarkWest Energy Partners, L.P. (NYSE:MWE) concerning the proposed acquisition of the Company by MPLX LP (“MPLX”) (NYSE: MPLX).

On 13 July, Ford Motor Company (NYSE:F) belongs to Consumer Goods sector. Its net profit margin is 2.20% and weekly performance is -1.01%. On last trading day company shares ended up $14.64. Ford Motor Company (NYSE:F) distance from 50-day simple moving average (SMA50) is -3.79%. On July 09, Ford Motor Company (NYSE:F) slated to begin contract talks with the United Auto Workers union in two weeks, plans to move production of two small cars outside of the U.S. from a Michigan factory, according to a person familiar with the matter.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) ended the last trading day at $11.42. Company weekly volatility is calculated as 4.05% and price to cash ratio as 7.52. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) showed a weekly performance of -6.01%. On July 08, AstraZeneca Pharmaceuticals Co., Ltd. and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced that top-line data demonstrate linaclotide met all primary and secondary endpoints, covering multiple abdominal and constipation symptoms, in a Phase III clinical trial of adults with irritable bowel syndrome with constipation (IBS-C). The trial was conducted primarily in China and the companies intend to file in early 2016 for China Food and Drug Administration (CFDA) approval to market linaclotide. Linaclotide is currently approved in the United States for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) and in a number of other countries for adults with IBS-C.

Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector. Its net profit margin is 51.70% and weekly performance is -0.96%. On last trading day company shares ended up $114.55. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 1.60%. On July 06, Gilead Sciences Inc. (NASDAQ:GILD) announced that it had submitted its Food and Drug Administration marketing application for its HIV cocktail pill containing rilpivirine, emtricitabine, and tenofovir alafenamide, abbreviated R/F/TAF.

Leave a Reply

Your email address will not be published. Required fields are marked *